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Abstract
Increasing evidence suggests that clock genes may be implicated in a spectrum of psychiatric diseases, including sleep and
mood related disorders as well as schizophrenia. The bHLH transcription factors SHARP1/DEC2/BHLHE41 and SHARP2/DEC1/
BHLHE40 are modulators of the circadian system and SHARP1/DEC2/BHLHE40 has been shown to regulate homeostatic
sleep drive in humans. In this study, we characterized Sharp1 and Sharp2 double mutant mice (S1/2-/-) using online EEG
recordings in living animals, behavioral assays and global gene expression profiling. EEG recordings revealed attenuated
sleep/wake amplitudes and alterations of theta oscillations. Increased sleep in the dark phase is paralleled by reduced
voluntary activity and cortical gene expression signatures reveal associations with psychiatric diseases. S1/2-/- mice display
alterations in novelty induced activity, anxiety and curiosity. Moreover, mutant mice exhibit impaired working memory and
deficits in prepulse inhibition resembling symptoms of psychiatric diseases. Network modeling indicates a connection
between neural plasticity and clock genes, particularly for SHARP1 and PER1. Our findings support the hypothesis that
abnormal sleep and certain (endo)phenotypes of psychiatric diseases may be caused by common mechanisms involving
components of the molecular clock including SHARP1 and SHARP2.
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Introduction
The circadian system has been implicated in the control of
alertness and clock genes have been associated with sleep and
mood disorders, such as familial advance sleep phase syndrome
(FASPS), depression, mania or bipolar disease (BD) [1–8], and
therapeutic approaches modulating the circadian system (‘chro-
notherapy’) may be promising to improve treatment of psychiatric
diseases [9,10]. Sleep-wake behavior represents the most obvious
behavioral output of the circadian system and nearly all
psychiatric diseases including autism and schizophrenia (SZ) are
characterized by irregular sleep-wake profiles [8,11,12]. In
addition to the circadian control, homeostatic processes regulate
vigilance states by increasing sleep drive and endurance [13–15].
Sleep serves a variety of vital functions. Prolonged wakefulness
results in compensatory or rebound sleep, and disruption of
normal sleep-wake cycles may contribute to psychiatric symptoms
and inflammatory as well neurodegenerative processes [16,17];
however, sleep deprivation has been shown to have short term
beneficial effects in depressive patients [18,19]. Reduced or
disturbed sleep likely contributes to cognitive impairments and
mood-related symptoms in psychiatric patients [8,20]. Recent data
support the notion that sleep is not only a distinct behavioral state
but is rather characterized by defined cellular processes, as shown
by monitoring sleep or wake associated cortical gene expression at
a global scale [21,22], and by progress in attributing sleep
associated brain oscillations, i.e. in the theta or delta range, to
functions in higher order neuronal plasticity [20,23].
Sleep-wake behavior is altered in clock gene mutant mice,
although the discrimination between circadian and homeostatic
processes in mutants with a disturbed clock is difficult [24–28].
The mechanisms that link clock gene function with sleep-wake
control and psychiatric diseases are just beginning to be explored
[8]. For example, mice expressing a truncated version of the
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CLOCK protein (ClockD19) are characterized by hyperactivity,
reduced sleep, lowered anxiety and depression-like behavior as
well as impaired neuronal synchronizations [29,30]. Moreover,
mice lacking NPAS2, the functionally redundant paralog of
CLOCK [31] which is, in contrast to CLOCK, prominently
expressed in the forebrain [32], are also hyperactive, display
reduced sleep and show altered sleep associated oscillations
[25,28].
SHARP1 (DEC2, BHLHE41) and SHARP2 (DEC1,
BHLHE40) are negative regulators of CLOCK and NPAS2 and
act as adaptation factors of the molecular clock [33–35]. Both
genes are involved in the entrainment of the circadian system to
altered external cues, yet the corresponding single and double null
mutants are characterized by a slight period shift but do not
display a disrupted circadian rhythm which indicates mainly
functional core clock mechanisms [35,36]. Period analysis,
resetting to advanced and delayed light-dark (LD) cycles as well
as nocturnal light pulses revealed gene dosage dependent
functional redundancy between both genes [35] and genetic
interactions with Per1 and Per2 [36,37]. Moreover, SHARP1/
DEC2 is involved in the regulation of sleep homeostasis in mice
and humans [38]. A single point mutation in the C-terminal
domain (P385R) found in a human family of ‘short’ sleepers
reduces the transcriptional repressive activity of SHARP1. In a
corresponding humanized mouse model, the duration of sleep is
reduced and more fragmented compared to control animals, and
the latter phenotype is strongly enhanced on a Sharp1 null
background [38]. With respect to sleep architecture, only a
moderate increase of non-rapid eye movement (NREM) sleep
during the early dark phase has been observed in Sharp1 null
mutants [38]. Therefore, the P385R mutant SHARP1 protein was
considered to act in a dominant-negative fashion.
Given the mild sleep architecture phenotype in Sharp1 null
mutants and the functional redundancy of SHARP1 and -2 in the
entrainment to external cues [35] it is possible that SHARP2 could
at least partially compensate for the loss of SHARP1. Conse-
quently, we analyzed sleep-wake behavior in Sharp1 and -2
double null mutant (S1/2-/-) mice. Our analysis revealed altered
sleep architecture in S1/2-/- mice with markedly attenuated light-
to-dark amplitude of the different vigilance states. Moreover,
daytime dependent changes in cortical gene expression and
behavioral analyses revealed associations of SHARP1/2 function
with endophenotypes of psychiatric diseases beyond the homeo-
static control of sleep.
Results
Attenuated Sleep-Wake Amplitudes in S1/2-/- mice
Given the relatively mild sleep phenotype of Sharp1 single
mutants [38] and the functional redundancy of SHARP1 and -2
[35], we focussed on the analysis of Sharp1 and -2 double mutant
mice (S1/2-/-). We performed EEG and EMG recordings on male
mice to monitor for sleep-wake patterns over consecutive 24 h
light-dark (LD) cycles. We determined the relative amounts of
NREM (or slow-wave), REM (or paradoxical) sleep and wakeful-
ness over 12 h light (L) and 12 h dark (D) periods and for the
entire 24 h LD period. Total wakefulness, REM and NREM
during 24 h of undisturbed sleep were similar in wild-type (WT)
and S1/2-/- animals (Figure 1A). However, there was a clear
difference in the distribution of sleep and wakefulness during L
and D. WT animals showed a substantial difference in the amount
of wakefulness, NREM- and REM-sleep between L and D,
whereas the sleep/wake amplitude was attenuated in S1/2-/-
animals (Figure 1B,C). Sleep-wake behavior was quantified as
relative L-D differences, which were significantly reduced in S1/
2-/- animals for all three vigilance states (p,0.01 for wake, p,0.05
for REM and NREM sleep) (Figure 1B). The relative difference in
the amount of wakefulness during the light and dark episodes is
exemplified for individual WT and S1/2-/- mice (Figure 1C). We
plotted the cumulated EEG data in 2 h bins to increase temporal
resolution (Figure 1D-F). NREM sleep was most prominently
altered in the two hours preceding lights-off (zeitgeber time (ZT)
10-12; reduced NREM) and in the middle of the dark phase
(ZT19-21; increased NREM; p,0.05; post-hoc test after 2-way
ANOVA with significant genotype6time interaction p,0.05)
(Figure 1E). REM sleep was reduced at ZT4-8 (p,0.05: post-hoc
test after 2-way ANOVA with significant genotype p,0.01 and
time p,0.0001 effects without significant genotype6time interac-
tion) (Figure 1F).
We sleep deprived S1/2-/- and control mice by gentle handling
(ZT0-6 = L1, 9761% efficient for both genotypes) to analyze
homeostatic sleep drive (Figure S1A–C). The amount of NREM
sleep after sleep deprivation (SD) revealed no significant differ-
ences in L2 (ZT7-12), at the beginning of D2 (ZT17) NREM sleep
was increased in S1/2-/- compared to WT mice (p,0.05) (Figure
S1B). The relative amount of REM sleep, however, was
significantly reduced in S1/2-/- mice (p,0.05) compared to WT
mice 2–4 h after the SD episode (ZT8-10) (Figure S1C). The
analysis of slow-wave activity (SWA) or NREM delta power after
SD revealed similar levels of rebound sleep in WT and S1/2-/-
mice compared to baseline values (Figure S2A). Nonetheless, we
observed consistent but not significantly elevated SWA in S1/2-/-
mice at almost all time points independent of SD (Figure S2A). We
also analyzed the REM sleep dominating synchronized oscillations
in the 5–9 Hz range (theta) (Figure S2B-D). Theta peak frequency
(TPF) was significantly higher at ZT7-12 in sleep deprived S1/2-/-
animals (TPF S1/2-/-: 7.6060.12 Hz) compared to undisturbed
(TPF WT 7.1760.12 Hz; p,0.05) and sleep deprived WT mice
(TPF WT: 7.2260.03 Hz; p,0.01) (Figure S2B). Without SD, no
spectral theta differences were observed in S1/2-/- versus WT
mice at ZT7-12 (Figure S2C). However, theta spectra were altered
between sleep deprived S1/2-/- and controls in the time period
between ZT7-12 (Figure S2D; 2-way ANOVA, p = 0.0047). The
increased TPF observed after SD in S1/2-/- mice was not
significantly different to the average values obtained for all sleep-
deprived and naı¨ve animals during the dark period and thus
occurs in the normal physiological range (ZT13-18 and ZT19-24)
(Figure S2B).
EEG analyses were complemented by assessing 24 h rest-
activity profiles monitored with voluntary wheel running. In this
assay, S1/2-/- mice displayed normal entrainment to the LD cycle,
but with a reduced wheel activity during D (Figure 1G), which
correlates with the increased relative amount of sleep in D
(Figure 1B). In L, we observed no significant differences in running
wheel activities between the genotypes possibly due to photic
masking of voluntary locomotor activity [39] (Figure 1G).
Disturbed activity dependent gene expression
Different vigilance states are characterized by specific cortical
gene expression profiles [21]. To identify molecular correlates of
the altered sleep-wake behavior and 24 h rest-activity profiles in
S1/2-/- mice, we first analyzed cortical gene expression of the
circadian marker gene Per2 and the activity-induced immediate-
early gene (IEG) product Fos in 4 h bins over a complete 24 h
cycle (Figure 1H,I). In line with previous observations [35] the
circadian profile of Per2 in the cortex was grossly normal,
however, with a slightly but significantly reduced amplitude in S1/
2-/- versus WT mice (p,0.001, 2-way ANOVA) (Figure 1H). In
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contrast, the diurnal amplitude of cortical mRNA expression of
the neuronal-activity marker Fos was preserved; but Fos
transcription was strongly reduced at ZT16 in S1/2-/- mice
compared to WT animals (p,0.001, 2-way ANOVA; p,0.001
post-hoc test at ZT16) (Figure 1I) correlating with the elevated
NREM sleep and reduced running wheel activity in D
Figure 1. Attenuated sleep-wake amplitude and activity profiles in S1/2-/- mice. A) Group means (6 SEM) of the total time spend in
different vigilance states over 24 h LD periods. The overall time of wake, NREM and REM sleep remained unaltered between genotypes. WT: n = 7,
filled bars S1/2-/-: n = 8, empty bars. B) Group means of light-dark or amplitude differences for wake, NREM and REM sleep. S1/2-/- animals showed a
significantly reduced light-dark amplitude for all vigilance states compared to WT animals (Egenotype F(1, 39) = 19.87, p,0.0001; Evigilance state F(2,
39) = 19.39, p,0.0001; Igenotype6vigilance state F(2, 39) = 1.9, p = 0.16; Post hoc two-tailed T-test: **: p,0.01 *: p,0.05). WT: n = 7, filled bars S1/2
-/-: n = 8,
empty bars. C) 24 h sleep-wake distribution plotted for representative individual WT (#26) and S1/2-/- (#828) mice with black areas given as relative
amount of wakefulness obtained from 5 min bins. Note the relative difference in the amount of wakefulness during the light and dark episodes in the
WT and the short periods of wakefulness in the light phase. In contrast, the S1/2-/- mouse displayed broadened periods of sleep and wakefulness
during the light and dark phases. D-F) Time course of vigilance states wakefulness (D), NREM (E) and REM sleep (F). Curves connect 2 h bin mean
values (6 SEM) expressed as percentage of recording time (Etime: NREM: F(11,120) = 9.74, p,0.0001; REM F(11,120) = 9.98, p,0.0001; Egenotype: NREM n.s.;
REM F(1,120) = 7.65, p,0.01 and Igenotype6time: Wakefulness F(11,120) = 2.06, p = 0.02; NREM: F(11,120) = 1.82, p = 0.05; REM: F(11,120) = 1.42, p = 0.17; * = p,
0.05 in two-tailed post hoc T-test. WT: n = 7, filled circles S1/2-/-: n = 8, empty circles. G) Diurnal wheel-running profiles depicted as accumulated
activities of all recordings over a 5-day period plotted as 18 min bins. S1/2-/- mice displayed a significantly altered activity profile in LD compared to
wild-type (WT) mice (Igenotype6time F(86,39040) = 1.92, p,0.0001) with reduced half maximal values of nocturnal activities at ZT 17.1 for S12
-/- mice
compared to WT controls with ZT 18.3. Bonferroni posttest revealed significantly reduced activities between ZT13 and 18 (pBonf,0.05). n = 12 each
genotype. H-I) Daytime dependent gene expression analysis of the circadian marker gene Per2 (H) and the activity-induced gene Fos (I) in the cortex.
Daytime dependent cortical expression of the circadian marker gene Per2 was not substantially altered in WT and S1/2-/- mice (H). In contrast, the
mRNA expression of the activity regulated marker gene Fos was significantly reduced in S1/2-/- mice at ZT16 compared to WT (I). n = 3 per timepoint
and genotype. Data were analyzed with 2-way ANOVA with Bonferroni posttest (pBonf) and Mann-Whitney test (pMW) for pairwise comparisons. E,
effect; I, interaction of factors.
doi:10.1371/journal.pone.0110310.g001
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(Figure 1E,G). To obtain a more comprehensive insight into the
changes in cortical gene expression in S1/2-/- mice, we performed
microarray analysis on cortical samples obtained from individual
WT and S1/2-/- mice harvested at two opposite time points of the
LD cycle (ZT4 – wake phase; and ZT16 – sleep phase; Figure 2A;
Table S1 and Table S2) where Fos expression differences were
most prominent. This analysis revealed profound sleep-wake
differences at the level of gene expression. Most prominently, the
number of transcripts upregulated at ZT16 compared to ZT4 was
substantially higher in WT (n = 22, corresponding to 21 genes with
2 probe sets detected for preproenkephalin Penk) than in S1/2-/-
mice (n = 5) (Table S1 and Table S2, see Table S3 for full gene
name descriptions). In accordance with the quantitative (q)RT-
PCR analysis (Figure 1H) and based on published results showing
an intact circadian clock in S1/2-/- mice [35,36] among the five
genes found to be significantly up-regulated in S1/2-/- cortex at
ZT16 were three canonical clock genes (Per1, Per2, Cry1)
although at slightly reduced induction levels (Figure 2A and Table
S1).
Wake-induced expression of transcripts encoding for neural
plasticity genes (i.e. IEG transcription factors such as Fos, Nr4a1,
Egr1, Ier1 and Junb and those related to inter- and intracellular
signalling such as Tac1, Penk, Dusp1/6, Drd2, Adora2a) was
almost completely abolished in the S1/2-/- mutants (Figure 2A
and Table S1). Within this cluster of genes were also the
oligodendrocyte/myelin markers Enpp2, Plp1 and Cldn11. By
qRT-PCR, we validated differential expression of selected genes in
independent groups of mice in LD and DD (Figure 2B and Table
S1). The analyses under constant darkness (DD) revealed a highly
similar attenuated amplitude ruling out potential light masking
effects.
Next, we used gene set enrichment analysis (GSEA) to identify
cellular processes potentially altered in S1/2-/- mice [40]. Similar
to the gene-by-gene analysis, we detected the most profound
differences when comparing WT and S1/2-/- array data obtained
Figure 2. Cortical gene expression signatures correlate with psychiatric disease states. A) Depicted are fold-changes of differentially
expressed genes at ZT4 versus ZT16 in the cortex of WT and S1/2-/- mice detected by microarray analyses. In WT mice, several genes were
upregulated with a fold-change of at least 1.5 at ZT16 (n = 22, Penk was detected by two independent probe sets) whereas this profile was strongly
attenuated in S1/2-/- mice with only 5 genes (marked with #) detected at the same cut-off (among those are 3 canonical clock genes Cry1, Per1 and
Per2 as well as Anln and Hspa1b) that follow a normal although reduced ‘circadian’ profile. Note, that Ttr was for graphical reasons omitted because of
its high fold-changes (Table S1). n = 2 per timepoint and genotype. B) Attenuated sleep-wake amplitude of Fos gene expression in the cortex of WT
and S1/2-/- mice in LD and DD. At ZT4 and ZT16 (where mice were kept under 12 h light and 12 dark conditions = LD; left panel) and at CT4 and CT16
(where mice were kept under constant darkness = DD; right panel) cortical Fos mRNA expression was analyzed with quantitative RT-PCR. n = 3 for
each genotype. C) GeneGo enrichment analysis based on hyper-geometric statistics of the top 10 ranked disease associations of the cortical gene set
(deregulated at ZT16 in S1/2-/- cortex compared to WT). This analysis revealed highly significant correlations with neurological and particularly
psychiatric disease classifications as indicated. Spelling of classifier 5 ‘Schizophrenia and Disorders with Psychotic Features’ is abbreviated as
indicated. MeSH ID, unique Medical Subject Heading disease identifier.
doi:10.1371/journal.pone.0110310.g002
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at ZT16. Among the most significantly up-regulated gene sets in
WT samples were several involved in cellular metabolism, such as
components of the proteasome and ribosome as well as genes
associated with oxidative phosphorylation (p-val,0.0001, FDR
q-val,0.05) (Figure S3). Again, these molecular adaptations
correlated with the attenuated sleep-wake/activity-rest amplitudes
observed in S1/2-/- animals. We also analyzed gene expression in
cortical samples obtained from WT and S1/2-/- mice after sleep
deprivation. mRNA levels of two housekeeping genes, Atp5b and
Actb, as well as Per2 remained unaltered between WT and S1/2-/-
mutants (Figure S4B). In contrast, SD-induced down-regulation of
Per1, Fos and Egr1 gene expression observed in WT animals was
markedly attenuated in S1/2-/- mice correlating with genotype
dependent REM sleep alterations at ZT10 (Figure S1C and S4B).
Molecular signatures reveal associations with psychiatric
disorders
In an unbiased approach, we applied software tools to detect
potential associations of daytime-dependent cortical gene expres-
sion signatures (Table S1) in S1/2-/- mice with particular disease
classifiers [41]. Among the ten most significant matches were seven
neurological medical subject heading (MeSH) classifiers and of
those five were related to mood or psychotic disorders, suggesting
a potential link between SHARP dysfunction and psychiatric
diseases beyond alterations in sleep (Figure 2C). We further
extended this analysis by applying pathway modeling algorithms to
daytime-regulated genes including SHARP1 and -2 as seed nodes
(Figure 3A). This approach aimed at detecting relationships
between transcriptionally regulated as well as unregulated but
functionally linked gene products to provide a more complete
picture [42]. We used the most stringent shortest path algorithm
that allows only 1-step indirect connections from curated
literature, pathway and protein-interaction databases (see Meth-
ods). The corresponding network model predicted close functional
interactions of 14 out of 23 gene products (64%) of the cortical
gene expression signature (including SHARP1 and -2) and 15
connecting nodes (Figure 3A). Two distinct sub-clusters emerged
from the network structure. One cluster connects components
involved in neuronal signalling (enkephalin A, substance P, A2A
and DRD2) and downstream effectors including negative regula-
tors (DUSP1,6 and HSPs) as well as transcriptional mediators (e.g.
FOS, EGR1, JUNB, NR4A1). The second cluster is comprised of
central components of the molecular clock (e.g. the core clock
transcription factors CLOCK, NPAS2 and BMAL1 as well as
clock feedback regulators and modifiers including SHARP1 and
-2, PER1 and -2, CRY1 and DBP and Rev-ERBalpha).
Remarkably, only SHARP1, PER1 and BMAL1 were detected
as connecting nodes between both clusters (Figure 3A). We
queried the GeneGo databases with all components of this
extended network to reveal associations with particular cellular
process and diseases in an unbiased way. Among the top ten
ranked disease associations were nine corresponding to psychiatric
disorders including depressive, affective and psychotic MeSH
classifiers (ranging from major depressive disorder [rank 1, p,
10226] to BD [rank 4, p,10223] and SZ [rank 9, p,10216])
(Figure 3B). Among the top ten ranked GO biological processes
are two circadian rhythm related ones (circadian rhythm [rank 1,
p,10222] and rhythmic processes [rank 2, p,10222]), and several
that refer to central metabolic processes most likely reflecting the
interaction between circadian clock function and cellular meta-
bolic control [43–45] (Figure 3C).
S1/2-/- mice display endophenotypes of psychiatric
disease
EEG recordings revealed a role of SHARP1/2 in the
homeostatic control of sleep and unsupervised analysis of cortical
gene expression profiles provided a possible link to psychiatric
diseases, particularly mood and psychotic disorders. Therefore, we
analyzed S1/2-/- mice to assess behavioral aspects that may be
relevant in the context of psychiatric diseases: including basic
behavior (motivation, exploratory, curiosity and anxiety), working
memory performance and sensorimotor gating (Figure 4–5 and
Figure S5–S8). In the open field test, we observed a highly
significant novelty-induced hyperactivity in an unfamiliar envi-
ronment (pMW (p value for Mann-Whitney test) ,0.0006;
Figure 4A), persistent during the entire test (effect of genotype
p = 0.0002; 2-way ANOVA, Figure 4B) and most prominent in
interval 3, 5 and 10 (pBonf (p values for Bonferroni post test),0.01,
,0.05 and ,0.05, respectively;). S1/2-/- mice spent more time in
the center (pMW,0.0004) of the test arena than controls possibly
indicating reduced anxiety or risk-taking behavior (Figure 4C).
Elevated plus maze (Figure S5A) and light-dark preference test
(Figure S5B), however, did not reveal alterations of anxiety-related
behavior. S1/2-/- mice spent similar time in closed arms in
elevated plus maze (pMW = 0.8693) and in the dark compartment
during light-dark preference test when compared with WT
controls (pMW = 0.1917). On the subsequent day after the open
field test, the same test arena was equipped with a ‘hole-board’ to
monitor nose pokes as an indicator of exploratory drive, curiosity-
related behavior. Whereas the total travelled distance did not differ
between the genotypes under more familiar conditions (Fig-
ure 4D), the number of nose pokes (Figure 4E) was significantly
reduced in S1/2-/- versus WT mice (pMW = 0.0014). However,
motivational behavior as assessed in tail suspension test
(pMW = 0.9456; Figure S5C) and in sucrose preference test
(p = 0.1719; 2-way ANOVA, Figure S5D) was unaltered.
As impairment of working memory is one of the core symptoms
of SZ and BD [46–48], we addressed working memory
performance of S1/2-/- mice using the Y-maze test. S1/2-/-
animals displayed an increased activity in this novel environment
performing more arm choices (p = 0.0022; 2-way ANOVA,
Figure 4F), mainly during the first 5 min (pBonf,0.01). Mutants
showed less alterations in Y-maze than controls (p = 0.0331; 2-way
ANOVA, Figure 4G) with the lower performance during interval
5–10 min (pBonf,0.05). We also observed working memory
deficits in a radial arm water maze (Figure 4H–J). In the visible
platform task, performance was similar in both genotypes
(p = 0.4236; 2-way ANOVA, Figure 4H) but S1/2-/- mice
displayed more working errors searching for a hidden platform
on the first (p = 0.0524; 2-way ANOVA, interaction genotype6
time p = 0.0486; Figure 4I) and on the second day of the
experiment (effect of genotype p = 0.0044 and genotype 6 time
p = 0.0422; 2-way ANOVA, Figure 4J) with the most prominent
difference during trial 3 (pBonf,0.001; Figure 4J).
To assess sensorimotor gating as an additional endophenotype
of several psychiatric diseases [49–51], S1/2-/- mice and WT
controls were tested in a prepulse inhibition (PPI) test under
normal conditions and after treatment with clozapine. We
performed the tests on 3 consecutive days with naı¨ve animals
(day 1), injected with vehicle (day 2) and after acute clozapine
treatment (3mg/kg; day 3).
To exclude possible effects of multiple testing on PPI, we first
exposed naı¨ve wild type animals (age-matched male C57Bl/6) on
three consecutive days to PPI (Figure S6). We did not observe
effects of multiple testing on PPI (p = 0.1539; 2-way ANOVA;
Endophenotypes of SHARP1 and SHARP2 Mouse Mutants
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Figure S6A) nor on startle response (p = 0.9724, 1-way ANOVA;
Figure S6B).
Naı¨ve S1/2-/- mice displayed pronounced impairment of PPI
(p = 0.0071; Figure 5A) with most significant difference at prepulse
75 and 80 dB (pBonf,0.01 and pBonf,0.05, respectively). Startle
response (Figure 5B) was similar in S1/2-/- mice and WT controls
(p = 0.9958; 2-way ANOVA) and was not influenced significantly
by vehicle injections (p = 0.1434; 2-way ANOVA).
Acute clozapine treatment (3 mg/kg) reduced startle response in
both genotypes to similar extend when compared with vehicle
injections (p = 0.0009; 2-way ANOVA, Figure 5B). Clozapine
diminished PPI in WT mice when compared to vehicle treated
animals (p = 0.0025; 2-way ANOVA, Figure 5C). Bonferroni
posttest yielded significant difference at 70 dB prepulse (pBonf,
0.01). Clozapine had no effects on PPI in S1/2-/- mice (p = 0.9716;
2-way ANOVA, Figure 5D).
S1/2-/- and control mice showed habituation to 120 dB pulse
during PPI assessment (naı¨ve: p,0.0001; Figure S7A; vehicle:
p = 0.0006; Figure S7B; clozapine: p = 0.0197; Figure S7C; 2-way
ANOVA) which was comparable between the genotypes in all
treatment groups (naı¨ve: p = 0.4766; vehicle: p = 0.6974; cloza-
pine: p = 0.6008; 2-way ANOVA).
We also assessed effects of vehicle and clozapine (3 mg/kg)
injections in the open field (Figure S8). Vehicle injection reduced
hyperactivity in S1/2-/- mutants and increased anxiety in WT and
to a lesser extend also in S1/2-/- mutants (pMW = 0.2380, Figure
S8A and pMW = 0.2250, Figure S8B). Clozapine treatment
dramatically reduced the overall activity (p,0.0001; Figure S8A)
and time spent in the center (p = 0.0009; Figure S8B) in both
Figure 3. Unbiased network modeling links cortical signaling with clock components via SHARP1, BMAL1 and PER1. A) Depicted is
the network model with the highest significance computed with all genes found to be differentially regulated in the cortex at ZT4 versus ZT16 (see.
Figure 2A, Tables S1-S3 and Figure S9 for description of symbols) including SHARP1 and -2. The network connects 14 seed nodes depicted as blue
circles (higher expression levels in WT are indicated by associated small red circles) extended by 13 interactors. SHARP1 and -2 are labeled by red
circles; all nodes added by the algorithm are not underlined by colored circles. The structure depicts two major clusters and places the circadian
regulators SHARP1 and SHARP2 as well as PER1 at central positions. The left cluster (n = 19 objects) is mainly comprised of cellular signaling
components (enkephalin A, substance P both encoded by Penk and the GPCRs A2A and DRD2) and downstream effectors including negative
regulators (DUSP1,6 and HSPs) as well as transcriptional mediators (e.g. FOS, EGR1, JUNB). The right cluster (n = 12) comprises central components of
the molecular clock (e.g. the core clock transcription factors CLOCK, NPAS2 and BMAL1 as well as clock feedback regulators and modifiers including
SHARP1 and -2, PER1 and -2, CRY1, DBP and NR1D1/Rev-ERBalpha). The extended network gene list was queried against the GeneGo database for
enriched correlations with diseases (B) and biological processes (C). Among the ten most significant disease associations were nine mental or mood
related disease classifications (B). Among the ten highest ranked biological processes were only circadian rhythm- (rank 1 and 2) and metabolism-
associated (rank 3–8) processes (C). MeSH ID, unique Medical Subject Heading disease identifier; GO ID, unique identifier of the gene ontology
biological process collection; p-values determined by hypergeometric tests.
doi:10.1371/journal.pone.0110310.g003
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Figure 4. S1/2-/- mice display novelty induced hyperactivity, decreased anxiety and exploratory behavior and working memory
disturbances. A–C) Open field test performed in a novel, unfamiliar test arena. WT: n = 24, S1/2-/-: n = 26. A) Novelty-induced hyperactivity in S1/2-/-
mice as assessed by moving distance in the open field (pMW= 0.0006). B) Analysis in 1 min bins yielded a significant Egenotype (F(1,48) = 16.46;
p = 0.0002). Moreover, Bonferroni posttest revealed the strongest difference between the genotypes in interval 3, 5 and 10 (pBonf,0.01, pBonf,0.05
and pBonf,0.05, respectively). C) Mutants spent more time in the center (pMW= 0.0004) of the test arena indicating reduced anxiety when compared
to controls. D-E) Hole board test performed with a subsequent modification of the open field setup by floor insert with holes. WT: n = 24, S1/2-/-:
n = 26. D) S1/2-/- mice displayed no alterations in the overall activity measured as total distance travelled. E) S1/2-/- mice performed less nose pokes
into holes (pMW=0.0014) indicating decreased curiosity-related behavior compared to WT. F-G) Y-maze test. WT: n = 23, S1/2
-/-: n = 20. F) S1/2-/- mice
showed increased activity in Y-maze test (Egenotype F(1,41) = 10.98; p = 0.0019) most evident in interval 0-5 min (pBonf,0.01). G) Mutant mice performed
less alterations in Y-maze than control animals (Egenotype F(1,41) = 4.86; p = 0.0331) and pBonf,0.05 for interval 5–10 min. H-J) S1/2
-/- mice display
impairment of working memory in the radial arm water maze (RAWM). WT: n = 29, S1/2-/-: n = 28. H) In the visible platform task, performance was
similar in both genotypes (Egenotype F(1,55) = 0.65; p = 0.4236). I-J) S1/2
-/- mice showed increased number of working errors searching for a hidden
platform on the first (I) (Egenotype F(1,55) = 3.93; p = 0.0524; Igenotype6time F(3,165) = 2.68; p = 0.0486) and the second (J) day of experiment (Egenotype
F(1,55) = 9.05; p = 0.0044) and Igenotype6time F(5,275) = 2.34; p = 0.0422). Bonferroni posttest revealed significant difference during the 3
rd trial of the
second day (pBonf,0.001). WT, black bars/circles. S1/2
-/-, white bars/circles. Data were analyzed with 2-way ANOVA with Bonferroni posttest (pBonf)
and Mann-Whitney test (pMW) for pairwise comparisons. ***: p,0.001; **: p,0.01; *: p,0.05. E, effect; I, interaction of factors.
doi:10.1371/journal.pone.0110310.g004
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genotypes. However, clozapine effects were stronger on S1/2-/-
mice regarding distance (interaction genotype 6 treatment
p = 0.0296, 2-way ANOVA) and time in center (interaction
genotype6 treatment p = 0.0665, 2-way ANOVA).
Discussion
Altered sleep architecture in S1/2-/- mice
In this study, we have analyzed the sleep architecture, daytime-
dependent gene expression in the cortex and behavior in SHARP1
and SHARP2 double deficient (S1/2-/-) mice. Our data show that
sleep-wake profiles, responses of REM sleep and theta oscillations
to sleep deprivation, running wheel behavior and activity-related
cortical gene expression are altered in S1/2-/- animals, although
the 24 h cumulated total amount of sleep and wakefulness and
overall circadian rhythmicity remain unaltered. The alteration of
sleep architecture in S1/2-/- mutants, however, does not
phenocopy mice that express the human SHARP1/DEC2(P385R)
protein which display a reduction in total sleep time [38]. This
implies that the P385R mutant SHARP1 protein does not act in a
‘simple’ dominant-negative fashion interfering with SHARP1/2
repressor functions [38], i.e. by forming heterotypic homo- or
heterodimers with ‘wild-type’ proteins. Since SHARP1 and
SHARP2 can homo- and heterodimerize [52] and function in a
context dependent fashion either as repressors and co-activators of
CLOCK, NPAS2 as well as other transcriptional regulators [35], it
might be possible that the mutant SHARP1/DEC2(P385R)
protein could be mechanistically specific e.g. by only affecting
discrete repressive functions. This hypothesis should be addressed
experimentally and might be helpful in understanding the
molecular mechanisms that cause distinct sleep phenotypes in
S1/2-/- mice versus those expressing the SHARP1/DEC2(P385R)
mutant protein. In addition, S1/2-/- mice display alterations e.g. in
REM sleep that have not been observed in SHARP1 single
mutants [38]. Moreover, we found that REM sleep associated
theta oscillations were altered in S1/2-/- mice upon sleep
deprivation. Thus, loss of SHARP function causes an altered
adaptability of environmental stressors at the level of neuronal
synchronizations which may be of relevance for psychiatric disease
related behavior such as anxiety [30,53].
SHARP1/2 mutants display ‘mixed-state’
endophenotypes of psychiatric diseases
In a novel environment, S1/2-/- mice display locomotor
hyperactivity and diminished anxiety comparable to mania-like
behavior. Diminished anxiety can be interpreted as increased risk
taking [54], one of symptoms of BD [55]. However, alterations in
other anxiety tests were absent; possibly because different anxiety
tests monitor distinct types of emotional behavior as suggested
Figure 5. S1/2-/- mice show alterations of prepulse inhibition (PPI) which are resistant to Clozapine treatment. A) S1/2-/- mice display
impairment of PPI (Egenotype F(1,43) = 7.99; p = 0.0071). Bonferroni posttest revealed significant difference in prepulse 75 und 80 dB (pBonf,0.01 and
pBonf,0.05, respectively). WT: n = 24, S1/2
-/-: n = 21. B) Startle response was similar in S1/2-/- mice and WT controls (Egenotype F(1,88) = 0.00; p = 0.9958)
and not influenced significantly by vehicle injections (Etreatment F(1,88) = 2.18; p = 0.1434). Acute clozapine treatment (3 mg/kg) reduced startle in both
genotypes to similar extend (Etreatment F(1,82) = 11.83; p = 0.0009 and Egenotype F(1,82) = 0.01; p = 0.9030). ‘No injections’ and ‘vehicle’ groups: WT: n = 25,
S1/2-/-: n = 21; clozapine: WT: n = 20, S1/2-/-: n = 20. C) Acute treatment with clozapine (cloz; 3 mg/kg; n = 20) reduced PPI in WT mice when compared
to vehicle (veh; n = 24) treated WT animals (Etreatment F(1,42) = 10.33; p = 0.0025). Bonferroni posttest confirmed significant difference when prepulse 70
dB was applied (pBonf,0.01). D) Acute treatment with clozapine (cloz; 3 mg/kg) did not influence PPI in S1/2
-/- mice (n = 20) when compared to
vehicle injected mutants (n = 21) (Etreatment F(1,39) = 0.00; p = 0.9716). Data were analyzed with 2-way ANOVA and Bonferroni posttest (pBonf). ***: p,
0.001; **: p,0.01; *: p,0.05. E, effect.
doi:10.1371/journal.pone.0110310.g005
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previously [56,57]. Contrasting anxiety phenotypes have also been
found in mice haploinsufficient for the SZ/BD risk gene
CACNA1c [58,59] and in mice heterozygous for the BD
associated gene Ank3 showing altered behavior in elevated plus
maze and light-dark preference but not in the open field test [60].
However, no hyperactivity was detected in S1/2-/- animals in a
more intimate environment resembling the phenotype of mice
with a dopamine transporter knockdown where mania-like
exploratory behavior is present in novel but diminished in a
familiar environment [61]. In S1/2-/- mice, specific exploration
measured by nose pokes was diminished resembling more
depression-like symptoms. Similarly, when monitored for the
24 h voluntary locomotor activity profile in home cage, S1/2-/-
mice displayed hypoactivity during the dark phase (D) which
correlates with the observed relative increase of sleep in D. The
locomotor hypoactivity, reduced exploratory drive and increased
sleepiness in the active phase in S1/2-/- mutants are more
reminiscent of a depression-like state. Mixed-state or paradoxical
phenotypes of mania- and depression-like behavior have previ-
ously been observed when inactivating CLOCK selectively in the
hypothalamus [62]. Mouse mutants lacking functional CLOCK or
NPAS2 show locomotor hyperactivity and reduced sleep in D
[28,29], which has been interpreted as mania-like behavior in
CLOCK deficient mice [29]. Therefore, SHARP1/2 mutant mice
meet selected ‘mixed-state’ criteria for face validity towards BD
similarly to Clock mutants [63]. Nonetheless, it is still unclear
which of the mixed-state phenotypes are a direct or indirect
consequence of loss of SHARP1/2 functions. It is possible that
feedback mechanisms operate at the molecular and behavioral
level that cause mutual relationships e.g. between sleep and
affective phenotypes seen in S1/2-/- mice.
Altered endophenotypes at the circuitry level
The spectrum of endophenotypes in S1/2-/- mice with
relevance for psychiatric diseases is further expanded by the
working memory impairments and PPI deficits. Working memory
deficits are prominent in SZ and BD [46–48] and corresponding
animal models [64–68]. In concordance with published data,
acute clozapine treatment reduced PPI in WT [67] but had no
further effect on the low PPI levels in S1/2-/- mice. Interestingly,
clozapine is also not effective in more than 50% of treatment
resistant schizophrenic patients [69]. Although clozapine had
differential effects on PPI, it reduced to a similar extend startle
amplitude in both S1/2-/- mutant and control mice which has
been described in mice [67,68] and human subjects [70]; however,
showing stronger sedative effects on S1/2-/- mutants. Resistance of
S1/2-/- mice towards clozapine in PPI may be partially related to
the blunted DRD2 expression in these mutants [71,72], although
other mechanisms might also be involved given the broad
pharmacological profile of clozapine. Therefore, S1/2-/- mice
may be a valuable model to test novel compounds or therapies to
overcome clozapine resistance.
Cortical gene expression profiling reveals associations
with psychiatric diseases
We applied unbiased bioinformatic algorithms to identify
biological process and disease associations with gene sets obtained
from cortical gene expression profiling in WT and S1/2-/- mice
[41,42]. These analyses use curator-indexed literature databases
and do not provide direct experimental evidence. Nonetheless,
these analyses identified several psychiatric diseases (particularly
mood- and psychotic disorders) correlating with SHARP1/2
dysfunction-associated cortical gene expression. To substantiate
these findings, we scanned the mouse phenotype database
provided by the Jax labs (www.informatics.jax.org/phenotypes.
shtml) and found that Drd2 and Adora2a mouse mutants were
associated with ‘hypoactivity’ (mouse phenotype ID MP:0001402)
[73,74] and display altered behavioral adaptability to psychostim-
ulants [75,76]. Polymorphisms in ADORA2A may modulate
psychomotor vigilance and sleep EEG [76] and it has been
previously noted that DRD2 variants are associated with mood
disorders [77]. In addition, DRD2 represents an interesting
pharmacological target for the treatment of psychosis [78] and
ADORA2A has been suggested as a target for the treatment of
psychiatric diseases [79]. Moreover, we detected attenuated gene
expression of three myelin genes (Enpp2, Plp1, Cldn11) in the
cortex of S1/2-/- mice. This finding provides an additional link
with psychiatric diseases since reduced expression of oligodendro-
cyte/myelin markers is among the most replicated molecular
observations in psychiatric diseases including SZ and major
depression, although an underlying mechanistic concept for these
observations is still missing [80–82].
Disintegration of activity-dependent and circadian
processes
Among the few upregulated genes in the cortex of S1/2-/- mice
at ZT16 were three canonical circadian factors (Per1, Per2 and
Cry1) indicating a functional clock in agreement with previous
observations [35,83]. The sleep-wake amplitude in expression of
these circadian genes, however, was attenuated, although not
completely abolished, as compared to that of plasticity-related
genes. It has been noted before that the expression of clock
regulated genes in the cortex is not strictly controlled by circadian
mechanisms only [21] which may explain the partially reduced
amplitude under LD and DD conditions in S1/2-/- mice. We also
detected the genes Penk and Tac encoding the neuropeptides
preproenkephalin and tachykinin as deregulated in the cortex of
S1/2-/- mice. These hormones have been associated with anxiety,
analgesic effects and altered stress responses [84,85]. It is therefore
possible that these and potentially other neuroendocrine factors
may have caused or modulated some of the behavioral alterations
observed in S1/2-/- mice.
Sleep-wake behavior is regulated by circadian and homeostatic
processes [13–15]. Therefore, the attenuated running wheel
profile of S1/2-/- mice in L, which is paralleled by increased
NREM sleep levels and reduced activity-regulated gene expres-
sion, could be driven by disturbance of a thus far unknown
homeostatic process. In consequence, an uncoupling of homeo-
static and circadian processes could explain the molecular and
behavioral alterations seen in S1/2-/- mice. The identification of
the postulated homeostatic process(es) altered upon loss of
SHARP1 and -2 could help to better understand the link between
the disturbed sleep architecture and the molecular and behavioral
consequences.
Network modelling of all deregulated genes including SHARP1
and SHARP2 revealed a bipartite assembly of activity/plasticity
genes and circadian factors that were connected by SHARP1 and
PER1. It may thus be possible that particularly SHARP1 and also
PER1 may be key regulators integrating plasticity-related as well
as circadian and homeostatic processes in the cortex. As shown in
this study, the loss of SHARP function results in a disintegration of
both processes consequently leading to psychiatric (endo)pheno-
types. Recent observations made with Sharp1/2 and Per1 triple
null mutant mice, however, revealed a genetic interaction of these
factors in the regulation of circadian locomotor activity [37]. In
light of our findings presented in this study, it might thus be
interesting to characterize sleep and behavior also in Sharp1/2 and
Per1 triple mutants.
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In summary, our findings support the hypothesis that abnormal
sleep and certain (endo)phenotypes of psychiatric diseases may be
caused by common mechanisms involving components of the
molecular clock including SHARP1 and SHARP2. Moreover,
genetically defined mouse models of circadian genes with distinct
(endo)phenotype profiles, such as S1/2-/- mice, may be useful for
pre-clinical treatment trials in the context of psychiatric diseases
including sleep and mood disorders.
Materials and Methods
Animal experiments
All animal experiments were conducted in accordance with
NIH principles of laboratory animal care and were approved by
the Government of Lower Saxony, Germany. The experiments
were performed with cohorts of adult male mice aged 3–5 months,
respectively. Cohorts of mice within experiments were age
matched (62 weeks). Parental single heterozygous mice were
independently backcrossed to C57Bl/6J for more than ten
generations as described previously [35]. Wild-type (WT) and
Sharp1 and -2 double mutant mice (S1/2-/-) were obtained from
double heterozygous breeding pairs [35,86]. All experimental
animals were group housed in the same ventilated sound-
attenuated rooms under a 12 h light/12 h dark schedule at an
ambient temperature of 21uC with food and water available ad
libitum. All experiments were performed blinded to genotypes.
Surgical implantation procedures
Surgery was performed under deep intraperitoneal anaesthesia
with Ketamine/Xylazine (100 mg/kg; 10 mg/kg). Two stainless
steel screws (diameter 0.7 mm; Plastics One) were implanted
epidurally in the skull over the right parietal cortex (1.7 mm lateral
to midline, 1.0 mm anterior to lambda) and the left frontal cortex
(1.7 mm lateral to midline and 1.5 mm anterior to bregma) to
derive the electroencephalogram (EEG). A third screw over the left
hemisphere served as anchor screw. For electromyographic (EMG)
recordings two stainless steel wires were inserted into the neck
muscles bilaterally. All electrodes were connected to a mouse-
adapted socket (Plastics One), which was fixed with dental acrylic
cement.
EEG Recordings
After surgery the animals were allowed to recover for at least 2
weeks before data acquisition. To habituate to recording
conditions animals were connected to the recording lead attached
to a swivel contact at least 4 days before the start of experiments.
Recordings were performed on three consecutive 24 h periods
starting at lights-on. Day one was not analyzed, day two served as
baseline recordings and on day three animals were sleep deprived
by gentle handling. EEG and EMG signals of four animals (two of
each genotype) were recorded simultaneously to equally distribute
environmental disturbances. EEG and EMG signals were ampli-
fied, filtered, analog-digital-converted at 256 Hz and stored on a
computer hard disk (Sleep Sign Acquisition, Kissei Comtec).
Three vigilance states, wakefulness (W), non rapid eye movement
sleep (NREM) and rapid eye movement sleep (REM), were
determined offline (Sleep Sign Analysis, Kissei Comtec) in epochs
of 4 s by visual assessment of EEG- and EMG-recordings. Epochs
containing more than one vigilance state were scored as the
prevailing one and epochs containing recording artefacts were
omitted from subsequent spectral analysis. The amount of each
vigilance state was expressed as percentage of recording time.
Spectral analysis and measurement of slow-wave-activity
For each 4 s epoch scored as NREM or REM sleep, EEG was
subjected to a fast Fourier Transformation (FFT) analysis, yielding
power spectra between 0.5 and 20 Hz with a 0.5 Hz resolution
(Sleep Sign Analysis, Kissei Comtec). Slow wave activity (SWA) in
NREM sleep was calculated as the mean power over the frequency
range between 0.5 and 4.0 Hz. All SWA measures were expressed
as percentage of the individual mean SWA over the last 900
NREM epochs in the baseline light period to correct for individual
differences in the absolute power.
Spectral analysis and determination of theta peak
frequency
EEG spectral profiles of REM sleep are dominated by
frequencies in the Theta band range. To determine the prevailing
frequency in REM sleep, the distribution of peak frequency was
calculated. Means of FFT spectra of artefact-free 4 s epochs were
calculated over two-hour intervals and the frequency of the
maximal power in the range between 5 and 10 Hz determined for
these mean frequency distributions.
Running wheel analysis of activity profiles
Activity data were recorded and evaluated using the ClockLab
data collection and analysis software (Actimetrics) as described
previously [35]. To obtain a full activity profile, 24 h accumulated
activities of running wheel recordings over a 5 day period were
analyzed in 18 min bins.
Tissue Sampling and gene expression analysis
Cortical tissue (bregma 0 to 22 mm) was isolated using a
‘rodent brain matrix’ 1 mm coronal slicer (ASI Instruments,
Warren, MI) from adult WT and S1/2-/- mice harvested at ZT0,
ZT4, ZT8, ZT12, ZT16, ZT20 and independent cohorts analyzed
at ZT4, ZT16, CT4 and CT16 (n = 3 for each genotype and time
point). Animals were kept 24 h under DD (12 h dark, 12 h dark)
before being sacrificed under dim red light for the analysis of all
CT time points. To analyze gene expression in response to sleep
deprivation, cortical samples were collected as described above
with a rodent brain matrix and pooled (n = 4 each time point and
genotype). RNA was prepared according to the manufacturer’s
protocols using RNeasy colums (Qiagen, Hilden, Germany) and
analyzed for integrity using the Bioanalyzer (Agilent Technolo-
gies). The minimal RNA-integrity (RIN) value threshold was 8.5.
For microarray analysis, one-round RNA amplification, labeling
and hybridization were essentially performed as previously
described [87]. Microarrays were scanned and pre-processed
according to standard protocols given by the manufacturer
(Affymetrix). Array data were analyzed using either R-scripts
(www.bioconductor.org) or the Genomics Suite (Partek). Differ-
ential gene expression over time was determined using ANOVA
and for genotype comparisons by applying moderate T-statistics
(using the corresponding bioconductor package). Selection cut-offs
were set to fold-changes.1.5 and corrected p-values ,0.05. Gene
set enrichment analysis (GSEA) of a priori defined sets of
functionally grouped genes was performed using the GSEA
software package downloaded from www.broadinstitute.org/gsea
and implemented locally. Analyses were performed with default
parameters (permutations set to 1000) and gene sets available in
the molecular signature database (MSigDB v3.0) as described
previously [87].
Quantitative PCR was performed with an ABI PRISM 7700
detection system (Perkin Elmer), essentially as described [88].
Primers directed against mouse transcripts (Table S4) were
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designed online at the Roche assay design center (www.roche-
applied-science.com/sis/rtpcr/upl/) and used in SYBRgreen
assays.
Gene Ontology and network analysis
Gene Ontology (GO) analysis was performed with Genomics
Suite (Partek) and MetaCore (GeneGo) using categories provided
by the GO consortium (www.geneontology.org). Gene-disease
association and network modelling was performed with MetaCore
(GeneGo) using manually curated disease databases compiled
from RefSeq annotations (http://www.ncbi.nlm.nih.gov/refseq/
rsg/) and literature minings listed as interlinked pubmed entries
with each gene in the corresponding disease database as
implemented in the software (www.genego.com). Dijkstra’s short-
est path algorithm with a maximum of steps set to 1 was applied
for network modeling and hypergeometric tests for GO enrich-
ment and gene/disease associations as implemented in the
software.
Behavioral analysis
Mice were tested for free running activity (in home cage), in
open field, hole board, elevated plus maze, light-dark preference,
tail suspension test, hot plate, Y-maze, radial arm water maze and
prepulse inhibition. Behavioral tests monitoring for novelty
induced activity, anxiety and curiosity (open filed and hole board),
anxiety (elevated plus maze and light-dark preference), pain
sensitivity (hot plate), escape motivation and/or depression (tail
suspension) and sensorimotor gating (prepulse inhibition test) were
essentially performed as described previously [64] Experiments
were performed between ZT2-ZT6 during light phase or between
ZT 14-18 in the wake-phase and under dim red light where
indicated.
Light-dark preference
The light dark preference test was conducted in a box consisting
of compartments of the same size: one with black walls (dark)
connected by a door with light compartment build of transparent
Plexiglas. Mice were placed in the transparent compartment facing
the wall and left undisturbed. Latency to enter the dark, the time
spent in the dark box and crossings between two compartments
were scored for 5 min.
Y-maze
Y-maze was performed using a custom made Y-shaped runway.
Mice were put into maze facing the wall and allowed to explore
undisturbed the maze for 10 min. The experiment was video
recorded and analyzed offline. The number of arm choices (as a
measure of activity) and the percent of alterations (choices of a
‘‘novel’’ arm, different than chosen before as a measure of working
memory) were scored. The apparatus was cleaned between
animals with 70% ethanol p.a. to avoid olfactory cues.
Radial arm water maze
Radial arm water maze (RAWM) was performed following a
published protocol [89] with minor changes using an in house built
setup based on the authors’ specifications containing six arms
extending out of a central area. The setup was built out of white
plastic and positioned in white painted water so that the walls
protruded 20 cm above the water surface. Briefly, mice were
trained in RAWM to search for a platform submerged 1 cm below
the water surface at the end of the goal arm. On day 1, animals
were given two trials to learn to escape from water on a platform
tagged with a flag (visible platform task) starting from alternating
arms. Next, the flag was removed, visual cues (contrast-reach
graphical forms like a cross, concentric circles, stripes etc.) were
fixed on terminal walls of arms and mice were trained during 4
trials to find a platform submerged under water surface (hidden
platform task). The duration of each trial (both in visible and
hidden task) was 90 s; during this time mice were allowed to swim
to the goal arm guided by visual cues. In case of an error defined
as choice of a different arm than the goal arm, mice were
immediately removed from the wrong arm, put gently again into
the start arm and released. Entries into a goal arm, even if the
platform was not located, were not counted as errors. If animals
entered the wrong arm and after being brought to the start
position repeated again the same wrong choice, this was counted
as a ‘‘working error’’. The procedure was repeated until mice
found a platform (cut off time of 90 s). If mice were not able to find
a platform within the given latency, they were gently guided to the
proper position and were allowed to stay on the platform for 20 s
for information acquisition. Intermittent to all trials, the water was
gently mixed to avoid olfactory cues by urination or defecation.
Mice were kept on the warm platform (37uC) to avoid body
hypothermia between trials.
Sucrose preference test
A sucrose preference test was set up in a standard plastic cage
(Makrolon Type II) with normal bedding and with food ad libitum.
Prior the experiment, two weight balanced water bottles were
placed on each cage and weighted 24 hours later to exclude side
preferences. On the second day, each cage was equipped with one
bottle filled with 4% sucrose solution and one with water prepared
freshly every day and provided at the same time point. Position of
bottles (left versus right) was changed daily. Liquid intake was
measured by weight of consumed water/sucrose solution over
24 h for 4 days.
Drugs
Clozapine was purchased by Sigma-Aldrich (Germany) and
dissolved in a drop of 0.1 M HCl, mixed with saline, pH adjusted
to 5.3. Mice were injected i.p. with Clozapine (3 mg/kg) or with
vehicle (saline pH 5.3) in volume of 10 ml/kg 30 min prior to
behavioral testing.
Statistical analysis
EEG and behavioral data are presented as means 6 standard
error of the mean (SEM) and were compared by ANOVA with
Bonferroni (Bonf) post-hoc tests for repeated measurements or
Mann-Whitney (MW) tests for genotype comparisons using
GraphPad Prism 4 and 5 (GraphPad Software, San Diego,
California). p values were indicated as pBonf or pMW, respectively.
Moderate T-statistics and ANOVA were applied for gene
expression data (using the corresponding R-packages at www.
bioconductor.org and Genomics Suite, Partek). For qRT-PCR
analysis the Mann-Whitney test was applied when normality
testing failed and the unpaired two-tailed T-test for data showing
normal distribution using GraphPad Prism 5. A p-values less than
0.05 were considered significant for all tests applied. Abbreviations
for 2way ANOVA in figure legends are as follows: E, effect; I,
interaction of factors.
Supporting Information
Figure S1 EEG recordings upon sleep deprivation. A–C)
Time course of the vigilance states wakefulness (A), NREM (B) and
REM sleep (C) after 6 h of sleep deprivation (SD) performed from
ZT0-6. Curves connect 2-h bin mean values (6SEM) expressed as
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percentage of recording time (Igenotype6time of day: wakefulness F(2,
20) = 0.23, p = 0.51; NREM F(2,20) = 0.41, p = 0.67; REM
F(2,20) = 0.69, p = 0.51). WT, n = 7, filled circles. S1/2
-/-, n = 8,
empty circles. Data were analyzed with 2-way ANOVA. *: = p,
0.05 in two-tailed post hoc T-test). I, interaction of factors.
(TIF)
Figure S2 Delta and theta wave oscillations of undis-
turbed sleep and upon sleep deprivation. A) Baseline slow-
wave activity and SD induced rebound sleep in S1/2-/- mice.
Slow-wave activity (SWA) was plotted over a 24 h period as
percentage of the individual mean SWA over the last 900 NREM
epochs in the baseline light period. Using 2-way ANOVA with the
factors genotype and time, we detected no significant differences
between baseline and SD recordings between WT and S1/2-/-
mice. However, a trend towards a higher SWA in S1/2-/- mice
was detected. WT: n = 7, S1/2-/-: n = 8. B) Group means (6SEM,
WT: black bars; S1/2-/-: white bars) for mean theta peak
frequency (TPF) during REM sleep in consecutive 6-h blocks
(L1 = ZT0-6; L2 = ZT7-12, D1 = ZT13-18, D2 = ZT17-24) of
baseline recordings (blank bars) and after 6-h SD (hatched bars).
TPF varied with time-of-day and was significantly higher in the
S1/2-/- group during the 6 h following SD (2-way ANOVA:
Egenotype F(3,66) = 2.99 p = 0.04; Etime F(2,66) = 4.61; p = 0.01;
Igenotype6time: F(6, 66) = 0.46, p = 0.83; asterisks indicate significanc-
es between genotypes in post hoc T-test, ** = p,0.01) WT: n = 7,
S1/2-/-: n = 8. C–D) Power distribution in the 5–10 Hz range
comparing fast-fourier transformed (FFT) EEG spectra of WT and
S1/2-/- during baseline conditions (C; Ifrequency6genotype
F(12,117) = 0.57, p = 0.8588) and after SD (D; Ifrequency6genotype
F(12,117) = 2.57, p = 0.0047). Note the significant shift of the theta
component particularly between 6 and 7 Hz (p,0.05, post-hoc T-
test). Data were analyzed with 2-way ANOVA. WT: n = 7, S1/
2-/-: n = 8. SD, sleep deprivation; base, baseline. E, effect; I,
interaction of factors.
(TIF)
Figure S3 Divergent gene expression differences at
ZT16 in the cortex of WT and S1/2-/- mice as revealed
by gene set enrichment analysis (GSEA). A) P-value versus
enrichment plot comparing cortical gene expression of WT with
S1/2-/- mice using the GENMAPP gene data sets. With a false-
discovery rate (FDR) q-value cut-off set at 0.25 (default of the
GSEA algorithm), six gene sets were found to be upregulated in
WT samples whereas only two were significantly upregulated in
S1/2-/- mice (labeled by a black ellipses). The normalized
enrichment score (NES) is plotted versus the FDR q-value (red
dots) and the nominal p-value (black dots). B) Statistical
parameters of the most significantly deregulated gene sets (FDR
q-value ,0.25). The most significantly WT versus S1/2-/-
upregulated gene sets at ZT16 correspond to molecular machin-
eries involved in protein/RNA synthesis and turnover as well as
oxidative phosphorylation, likely reflecting the higher metabolic
demand in WT animals at ZT16 due to increased activity and
wakefulness. In S1/2-/- cortex, only two (highly similar) gene sets
comprising class A and peptide GPCRs were detected as
upregulated. SIZE, number of genes; ES, Enrichment score;
NES, normalized enrichment score; Nom p-val, nominal p-value;
FDR q-val, false discovery rate corrected q-value; FWER p-val,
family wise error rate. C-D) Enrichment plots of the top
deregulated gene sets encoding for components of proteasome
(gene rank order depicted as vertical lines left-shifted = up in WT)
and members of the class A GPCR family (gene rank order
depicted as vertical lines right-shifted = up in S1/2-/-). n = 2 per
timepoint and genotype.
(TIF)
Figure S4 Altered gene expression profiles of control,
circadian and activity-regulated genes in the cortex of
WT and S1/2-/- mice under baseline and sleep depriva-
tion conditions. A) Schematic drawing of the experimental
schedule. WT and S1/2-/- controls (base) and WT and S1/2-/-
animals that were sleep deprived from ZT0-6 (SD) were sacrificed
at ZT10-12 for cortex preparations and marker gene expression
analysis (n = 4 per each condition and genotype). B) Relative gene
expression changes of control (Atp5b, Actb), selected circadian
(Per1, Per2) and immediate early gene products (Fos, Egr1) in
cortex samples plotted as fold changes between baseline and SD
values (base/SD) for WT and S1/2-/- groups.
(TIF)
Figure S5 S1/2-/- mice show normal behavior in
elevated plus maze, light-dark preference and tail
suspension test. A) S1/2-/- mice display normal performance
spending similar time in closed arms in elevated plus maze when
compared with WT controls (pMW = 0.8693). WT: n = 23, S1/2
-/-:
n = 21. B) Time spent in the dark compartment during light-dark
preference test was similar between both genotypes
(pMW = 0.1917). WT: n = 25, S1/2
-/-: n = 18. C) Tail suspension
test did not found significant difference in struggling behavior in
S1/2-/- mice (pMW = 0.9456). WT: n = 24, S1/2
-/-: n = 21. D) S1/
2-/- mice consume similar volume of sucrose solution as WT
controls (Egenotype F(1,41) = 1.93; p = 0.1719). WT: n = 23, S1/2
-/-:
n = 20. wt: black bars. S1/2-/-: white bars. Data were analyzed
with 2-way ANOVA or Mann-Whitney test (pMW) for pairwise
comparisons. E, effect.
(TIF)
Figure S6 Multiple testing has no significant effects on
prepulse inhibition (PPI) in control C57Bl/6 wild type
mice. A) C57Bl/6 wild type mice (n = 11) were tested in PPI test
on three consecutive days. There are no significant effects of
multiple testing on PPI observed (Etime F(2,60) = 1.93; p = 0.1539).
B) Startle response was similar on three testing days (p = 0.9724).
Data were analyzed with 2-way ANOVA (A) and 1-way ANOVA
(B). E, effect.
(TIF)
Figure S7 SHARP1/2 mutant and control mice show
similar habituation to 120 dB pulse. A) Naı¨ve (not injected)
S1/2-/- mice and their wildtype littermates showed comparable
habituation (Etime F(1,44) = 21.92; p,0.0001) which was similar
between the genotypes (Egenotype F(1,44) = 0.52; p = 0.4766). WT:
n = 25; S1/2-/-: n = 21. B) Mice injected with vehicle display
habituation (Etime F(1,44) = 13.73; p = 0.0006) which is not altered
in mutants (Egenotype F(1,44) = 0.15; p = 0.6974). WT: n = 25; S1/
2-/-: n = 21. C) Animals treated with clozapine (3 mg/kg)
habituate to startling pulse (Etime F(1,38) = 5.93; p = 0.0197)
independent of the genotype (Egenotype F(1,38) = 0.28; p = 0.6008).
WT: n = 20; S1/2-/-: n = 20. Data were analyzed with 2-way
ANOVA. E, effect.
(TIF)
Figure S8 S1/2-/- mice respond stronger to clozapine
treatment in the open field than WT controls. A) In a
familiar open field box, hyperactivity in vehicle injected S1/2-/-
mice was not evident (pMW = 0.2380). Clozapine reduced distance
travelled (Etreatment F(1,38) = 103.89; p,0.0001). A 2-way ANOVA
yielded a significant Igenotype6treatment (F(1,38) = 5.11; p = 0.0296). B)
Vehicle treated S1/2-/- mice showed tendency to spend more time
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in the center of the familiar test arena (pMW = 0.2250). Time spent
in the center of the open field was reduced by clozapine
(F(1,38) = 13.10; p = 0.0009) in both genotypes. However, clozapine
effects were stronger in S1/2-/- mice (Igenotype6treatment
F(1,38) = 3.57; p = 0.0665). Vehicle treated mice: WT: n = 25; S1/
2-/-: n = 21; clozapine: WT: n = 20; S1/2-/-: n = 20.E, effect; I,
interaction of factors.
(TIF)
Figure S9 Description of network objects. Graphical
symbols describing functional classification of network objects
(nodes = genes or functionally grouped genes; edges =
connections between nodes) represent default settings by the
MetaCore software as depicted.
(TIF)
Table S1 Genes differentially regulated at ZT4 versus
ZT16 in cortex samples of WT and S1/2-/- mice. The
selection cut-off was set to fold-change (FC) of at least 1.5 and p-
value of ,0.05 in WT (including all genes/probe sets with yellow
and blue background). Note, that Penk was detected with two
probe sets to be upregulated at ZT16 in the WT cortex and that
only one gene (Chl1) showed a significant downregulation at ZT16
(indicated by a negative FC). In S1/2-/- mice, five genes were
detected to be significantly de-regulated between ZT4 and ZT16
with a p-value ,0.05 (blue background), the corresponding FC
values were, however, reduced compared to the WT. (n = 4
independent samples per genotype and two replicates per time-
point, p,0.05 was considered significant by ANOVA). We
validated the attenuated cortical gene expression in S1/2-/- mice
with quantitative RT-PCR (qRT-PCR) for 10 genes in LD and
DD (indicated at the table on the right: ZT4 vs 16 and CT4 vs 16,
correspondingly (n = 3 per timepoint per genotype).
(TIF)
Table S2 Normalized expression values of microarray
data. Depicted are the means and corresponding standard
deviation (SD) of normalized microarray data from ZT4 and
ZT16 cortex samples of WT and S1/2-/- mice (n = 2 per timepoint
per genotype).
(TIF)
Table S3 List of protein names, gene symbols and
synonyms.
(TIF)
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